Trial Profile
A Randomised, Double-blind, Parallel Groups, Placebo-controlled, Single-centre Pilot Study Assessing the Tolerability of Quinagolide in a Dose-titration Regimen in Oocyte Donors at Risk of Developing Ovarian Hyperstimulation Syndrome.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Quinagolide (Primary)
- Indications Ovarian hyperstimulation syndrome
- Focus Adverse reactions
- 31 May 2012 Status changed from completed to recruiting as reported by European Clinical Trials Database.
- 18 Sep 2009 Actual end date changed from Nov 2008 to Oct 2008 as reported by ClinicalTrials.gov.
- 18 Sep 2009 Actual end date changed from Nov 2008 to Oct 2008 as reported by ClinicalTrials.gov.